Brugger P
Pensionsversicherungsanstalt der Arbeiter, Ludwig-Boltzmann Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Z Kardiol. 1989 Aug;78(8):510-8.
The anti-arrhythmic efficacy of barucainide, a new class IB anti-arrhythmic agent, was evaluated in an open-label therapeutic study in a total of 15 patients with coronary artery disease. The majority of patients had a history of myocardial infarction. After a 3-day placebo run-in period barucainide was administered at a dose of 150 mg b.d. for 5 days followed by a 4-day placebo wash-out period. 24-h Holter monitorings were recorded in the run-in period, on day 4 of the treatment period, and on day 3 of the wash-out period. In addition, plasma levels were determined in all three periods. Statistical evaluation of the 24-h arrhythmia analyses revealed a decrease of premature ventricular contractions (PVCs) in all treated patients. Before treatment PVCs occurred at a median of 92.4/h (minimum 19/maximum 1537 PVCs/h); this value was reduced during treatment to a median of 7.9 (0/427) PVCs/h (p less than 0.01). A similar result was also found for the couplets which decreased significantly from a median (min/max) of 0.6 (0/11)/h before treatment with barucainide to 0.1 (0/3)/h after treatment (p less than 0.05). In 10 of 15 patients premature ventricular contractions were reduced by more than 80%. Ventricular tachycardia present in 4 of 15 patients was suppressed in all cases. Barucainide had only a slight effect on PQ and QTc intervals, QRS duration, heart rate, and blood pressure.
新型ⅠB类抗心律失常药物巴鲁卡胺的抗心律失常疗效在一项开放性治疗研究中进行了评估，该研究共纳入15例冠心病患者。大多数患者有心肌梗死病史。经过3天的安慰剂导入期后，巴鲁卡胺以每日两次、每次150毫克的剂量给药5天，随后是4天的安慰剂洗脱期。在导入期、治疗期第4天和洗脱期第3天进行24小时动态心电图监测。此外，在所有三个时期测定血浆水平。对24小时心律失常分析的统计评估显示，所有接受治疗的患者室性早搏（PVC）均减少。治疗前PVC的中位数为每小时92.4次（最小值19次/小时/最大值1537次PVC/小时）；治疗期间该值降至中位数每小时7.9次（0/427）PVC（p<0.01）。成对室性早搏也有类似结果，从巴鲁卡胺治疗前的中位数（最小值/最大值）每小时0.6次（0/11）显著降至治疗后的每小时0.1次（0/3）（p<0.05）。15例患者中有10例室性早搏减少超过80%。15例患者中有4例出现的室性心动过速在所有病例中均得到抑制。巴鲁卡胺对PQ和QTc间期、QRS时限、心率和血压只有轻微影响。
